{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:48:49Z","timestamp":1790113729417,"version":"4.0.1"},"reference-count":38,"publisher":"Microbiology Society","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background.<\/jats:bold>\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    is a key pathogen in cystic fibrosis (CF), driving pulmonary decline and exhibiting resistance through virulence factors and adaptive mutations. Cefiderocol (FDC) is a novel siderophore cephalosporin with activity against Gram-negative bacteria. We aimed to assess the\n                    <jats:italic>in vitro<\/jats:italic>\n                    efficacy of FDC against\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    isolates in a CF population.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods.<\/jats:bold>\n                    The study was conducted in a tertiary hospital with a specialist adult CF service. All first isolates of significant respiratory pathogens among this cohort are cryopreserved at \u221280\u2009\u00b0C. Antimicrobial susceptibility testing to FDC was performed as per European Committee on Antimicrobial Susceptibility Testing Disk-Diffusion (version 10) for all stored isolates of\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    from 2017 to 2022 inclusive.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results.<\/jats:bold>\n                    Eighty-five isolates from seventy-one patients were included. Resistance phenotypes comprised 19% (\n                    <jats:italic>n<\/jats:italic>\n                    =16) multidrug-resistant (MDR), 16% (\n                    <jats:italic>n<\/jats:italic>\n                    =14) extensively drug-resistant (XDR) and 24% (\n                    <jats:italic>n<\/jats:italic>\n                    =20) pandrug-resistant (PDR), with 24\u2009% (\n                    <jats:italic>n<\/jats:italic>\n                    =20) exhibiting the mucoid phenotype. Overall, 85% of isolates were susceptible to FDC, with a mean inhibition zone of 25.2\u2009mm. Antimicrobial activity was retained in 81% of MDR, 86% of XDR, 60% of PDR and 90% of mucoid isolates. Seventy-four per cent of meropenem-non-susceptible isolates remained susceptible to FDC, compared with lower susceptibility to ceftolozane\u2013tazobactam (42%), tobramycin (36%) and ciprofloxacin (22%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    FDC exhibited excellent\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    from adults with CF, including highly resistant and mucoid phenotypes. These findings highlight its potential as a salvage option in this high-risk population and provide the first Irish surveillance data to inform antimicrobial stewardship and future clinical use.\n                  <\/jats:p>","DOI":"10.1099\/acmi.0.001001.v3","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:16:34Z","timestamp":1758294994000},"source":"Crossref","is-referenced-by-count":1,"title":["In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis"],"prefix":"10.1099","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1207-4352","authenticated-orcid":false,"given":"Saied","family":"Ali","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Royal College of Surgeons in Ireland, Dublin, Ireland"},{"name":"Department of Clinical Microbiology, St. Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"McDermott","sequence":"additional","affiliation":[{"name":"Department of Clinical Microbiology, St. Vincent\u2019s University Hospital, Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"345","reference":[{"key":"R1","article-title":"Home | Cystic Fibrosis Foundation","year":"2025"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00006512"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.10127"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2020.0602"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1101\/319004"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00591-2"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02171-20"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020929988"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.21608\/ejmm.2022.262698"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad107"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab311"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00194-23"},{"key":"R14","article-title":"About Us","year":"2025"},{"key":"R15","article-title":"Hospital Related Guidelines","year":"2025"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac080"},{"key":"R17","article-title":"EUCAST Disk Diffusion Test Methodology"},{"key":"R18","article-title":"Guidance document on broth microdilution testing of cefiderocol","year":"2024"},{"key":"R19","article-title":"EUCAST warnings concerning antimicrobial susceptibility testing products or procedures"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00951-20"},{"key":"R21","article-title":"Cystic fibrosis: diagnosis and management","year":"2017"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.2.194-222.2002"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1016\/s1526-0550(02)00003-3"},{"key":"R24","article-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report 2023","year":"2024"},{"key":"R25","doi-asserted-by":"crossref","first-page":"e03047","DOI":"10.1128\/spectrum.03047-23","article-title":"In vitro activity of cefiderocol against Pseudomonas aeruginosa isolated from cystic fibrosis patients","volume":"11","author":"Monogue","year":"2023","journal-title":"Microbiol Spectr"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.11.014"},{"key":"R27","article-title":"Cefiderocol Injection","year":"2020"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200812-1845PP"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2014.03.010"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020974003"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02531-16"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2003.08.009"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.11.007"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01990-21"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-022-04526-0"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz123"}],"container-title":["Access Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/acmi\/10.1099\/acmi.0.001001.v3?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:16:35Z","timestamp":1758294995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/acmi\/10.1099\/acmi.0.001001.v3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1099\/acmi.0.001001.v3","relation":{"has-preprint":[{"id-type":"doi","id":"10.1099\/acmi.0.001001.v2","asserted-by":"subject"},{"id-type":"doi","id":"10.1099\/acmi.0.001001.v1","asserted-by":"subject"},{"id-type":"doi","id":"10.1099\/acmi.0.001001.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1099\/acmi.0.001001.v2","asserted-by":"object"}]},"ISSN":["2516-8290"],"issn-type":[{"value":"2516-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}